In vitro activity of novel antifolates against human squamous carcinoma cell lines of the head and neck with inherent resistance to methotrexate
- 18 July 1992
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 51 (6) , 909-914
- https://doi.org/10.1002/ijc.2910510613
Abstract
A series of 7 human squamous carcinoma cell lines of the head and neck (HNSCC), grown in standard medium containing high folate concentrations and in “folate-conditioned” medium containing nanomolar concentrations of folates, were all found to be sensitive (IC50: ⩽50 nM) in growth-inhibition studies to methotrexate (MTX) following drug exposure for 7 days. However, when MTX exposure was limited to 24 hr, only 2 out of 7 HNSCC cell lines were sensitive to MTX (IC50: 250 μM). In these last 3 cell lines, the mechanism of resistance was not correlated with altered membrane transport of MTX or changes in dihydrofo-late reductase activity, but rather was associated with a 3-fold lower activity of intracellular folylpolyglutamate synthase (FPGS) activity compared to MTX-sensitive HNSCC cells. The 3 cell lines exhibiting inherent resistance to a short exposure to MTX, however, did not show inherent cross-resistance after exposure for 24 hr to one or more of 3 novel antifolate compounds. These compounds, which appear to be more efficiently transported and polyglutamylated than MTX, include: 10-ethyl-10-deazaami-nopterin (10-EdAM), 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI-198,583), and 5, 10-dideazatetrahydrofo-lic acid (DDATHF). These results indicate that antifolate membrane transport and intracellular FPGS activity are important factors in determining sensitivity or resistance of HNSCC cells to short-term antifolate compound exposures.Keywords
This publication has 15 references indexed in Scilit:
- Index of subjectsAnnals of Oncology, 1992
- Mechanisms of acquired resistance to methotrexate in a human squamous carcinoma cell line of the head and neck, exposed to different treatment schedulesEuropean Journal of Cancer and Clinical Oncology, 1991
- The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)Biochemical Pharmacology, 1991
- In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neckCancer, 1991
- The Role of Cellular Folates in the Enhancement of Activity of the Thymidylate Synthase Inhibitor 10-Propargyl-5,8-dideazafolate against Hepatoma Cells in Vitro by Inhibitors of Dihydrofolate ReductaseJournal of Biological Chemistry, 1989
- A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesisJournal of Biological Chemistry, 1989
- A methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates.Journal of Biological Chemistry, 1984
- Development of methotrexate resistance in a human squamous cell carcinoma of the head and neck in culture.Proceedings of the National Academy of Sciences, 1984
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976